MyFinsight
Home
Blog
About
US
$1,114,500K
(18.43%↑ Y/Y)
Non Us
$801,900K
(-14.47%↓ Y/Y)
Royalty Attributed To
OCREVUS
$381,400K
(7.80%↑ Y/Y)
Biogen's share of pre-tax
profits in the u.s. for...
$125,700K
(16.71%↑ Y/Y)
Other revenues from
anti-cd20 therapeutic...
$6,400K
(10.34%↑ Y/Y)
Contract Manufacturing
And Other Revenue
$232,400K
(3.29%↑ Y/Y)
Royalty
$10,000K
(-48.98%↓ Y/Y)
Product
$1,916,400K
(2.01%↑ Y/Y)
Revenuesfromanticd20therapeuticprograms
$513,500K
(9.89%↑ Y/Y)
Product And Service
Other
$242,400K
(-0.90%↓ Y/Y)
LEQEMBICollaboration
$63,700K
(16.03%↑ Y/Y)
Total revenue
$2,736,000K
(3.42%↑ Y/Y)
Income before income
tax (benefit)...
$132,400K
(-82.20%↓ Y/Y)
Total cost and expense
$2,603,600K
(36.92%↑ Y/Y)
Net income
attributable to biogen inc
$97,500K
(-84.64%↓ Y/Y)
Income tax (benefit)
expense
$34,900K
(-68.04%↓ Y/Y)
Cost of sales,
excluding amortization...
$776,900K
(28.41%↑ Y/Y)
Selling, general and
administrative
$709,700K
(21.57%↑ Y/Y)
Research and development
$529,600K
(32.73%↑ Y/Y)
Amortization and impairment
of acquired...
$168,200K
(28.50%↑ Y/Y)
Restructuring charges
$165,400K
(23728.57%↑ Y/Y)
Acquired in-process
research and...
$164,000K
(251.93%↑ Y/Y)
Collaboration profit
sharing/(loss reimbursement)
$68,800K
(-8.27%↓ Y/Y)
Other (income)
expense, net
-$18,500K
(62.01%↑ Y/Y)
(gain) loss on fair
value remeasurement...
$2,500K
(-81.06%↓ Y/Y)
Back
Back
Income Statement
Biogen-svg
source: myfinsight.com
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)